Selenium supplementation for polycystic ovary syndrome: a meta-analysis of randomized controlled trials

source extracted confidence: high 2026-04-09
#female #humans #polycystic-ovary-syndrome #selenium #randomized-controlled-trials-as-topic

Selenium supplementation for polycystic ovary syndrome: a meta-analysis of randomized controlled trials

Wu et al., 2022 | Gynecol Endocrinol | Meta Analysis

Citation

Wu Pei-Yu, Tan Xianzu, ... Lou Jin-He. Selenium supplementation for polycystic ovary syndrome: a meta-analysis of randomized controlled trials. Gynecol Endocrinol. 2022-Nov;38(11):928-934. doi:10.1080/09513590.2022.2118709

Abstract

Introduction: The efficacy of selenium supplementation was elusive for polycystic ovary syndrome. This meta-analysis aimed to explore the efficacy of selenium supplementation for polycystic ovary syndrome. Methods: PubMed, EMbase, Web of science, EBSCO, Cochrane library database, CNKI, Chongqing VIP database and Wanfang databases have been searched through July 2022 and we included randomized controlled trials (RCTs) reporting the effect of selenium supplementation versus placebo in patients with polycystic ovary syndrome. Results: Five RCTs were included in the meta-analysis. Compared with placebo group for polycystic ovary syndrome, selenium supplementation was associated with significantly reduced total testosterone (SMD=-0.42; 95% CI=-0.78 to -0.06; p = 0.02) and cholesterol (SMD=-0.71; 95% CI=-1.41 to -0.02; p = 0.04), but revealed no remarkable influence on SHBG (SMD=-0.52; 95% CI=-1.29 to 0.25; p = 0.19), triglyceride (SMD=-1.45; 95% CI=-3.62 to 0.73; p = 0.19), LDL (SMD=-0.17; 95% CI=-0.72 to 0.37; p = 0.53), FPG (SMD=-0.95; 95% CI=-3.72 to 1.82; p = 0.50) or HOMA-IR (SMD=-0.51; 95% CI=-3.79 to 2.77; p = 0.76). Conclusions: Selenium supplementation may be able to improve the metabolic response for polycystic ovary syndrome, and this finding should be interpreted with caution.

Key Findings

Five RCTs were included in the meta-analysis. Compared with placebo group for polycystic ovary syndrome, selenium supplementation was associated with significantly reduced total testosterone (SMD=-0.42; 95% CI=-0.78 to -0.06; p = 0.02) and cholesterol (SMD=-0.71; 95% CI=-1.41 to -0.02; p = 0.04), but revealed no remarkable influence on SHBG (SMD=-0.52; 95% CI=-1.29 to 0.25; p = 0.19), triglyceride (SMD=-1.45; 95% CI=-3.62 to 0.73; p = 0.19), LDL (SMD=-0.17; 95% CI=-0.72 to 0.37; p = 0.53), FPG (

Outcomes Measured

  • Requires manual extraction

Population

Field Value
Population polycystic ovary syndrome
Sample Size See abstract
Age Range See abstract
Condition See abstract

MeSH Terms

  • Female
  • Humans
  • Polycystic Ovary Syndrome
  • Selenium
  • Randomized Controlled Trials as Topic
  • Testosterone
  • Dietary Supplements

Evidence Classification

  • Level: Meta Analysis
  • Publication Types: Meta-Analysis, Journal Article
  • Vertical: selenium

Provenance

Source extracted via PubMed E-utilities API on 2026-04-09